drugset / Trial / NCT04461600
A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.
Timeline
- Start
- 2020-08-14
- Primary completion
- 2022-03-23
- Completion
- 2022-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AL101 | Small molecule | 4 mg | — |
| Subject | AL101 | Small molecule | 6 mg | — |